P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn’s Disease – results from a tertiary IBD centre

M Snehali; A Ahmed; S Ghosh; M Iacucci; U N Shivaji

doi:10.1093/ecco-jcc/jjad212.0678

P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn’s Disease – results from a tertiary IBD centre

M Snehali
, A Ahmed
, S Ghosh
, M Iacucci
, U N Shivaji

University of Birmingham
University of Birmingham
Narayana Health

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	i1072-i1072
Journal	Journal of Crohn's and Colitis
Volume	18
Issue number	Supplement_1
DOIs	https://doi.org/10.1093/ecco-jcc/jjad212.0678
Publication status	Published - 24 Jan 2024
Event	19th Congress of ECCO - Stockhom, Sweden Duration: 21 Jul 2024 → 24 Jul 2024

Access to Document

10.1093/ecco-jcc/jjad212.0678Licence: Other

https://academic.oup.com/ecco-jcc/article/18/Supplement_1/i1072/7586719

Researcher from University Hospitals Birmingham Reports on Findings in Crohn's Disease (P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn's Disease - results from a tertiary IBD centre)
Iacucci, M.
12/02/24
1 item of Media coverage
Press/Media

Cite this

@article{b096f04cad2d495ba661fbca454aba53,

title = "P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn{\textquoteright}s Disease – results from a tertiary IBD centre",

author = "M Snehali and A Ahmed and S Ghosh and M Iacucci and Shivaji, \{U N\}",

year = "2024",

month = jan,

day = "24",

doi = "10.1093/ecco-jcc/jjad212.0678",

language = "English",

volume = "18",

pages = "i1072--i1072",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "Supplement\_1",

note = "19th Congress of ECCO ; Conference date: 21-07-2024 Through 24-07-2024",

}

TY - JOUR

T1 - P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn’s Disease – results from a tertiary IBD centre

AU - Snehali, M

AU - Ahmed, A

AU - Ghosh, S

AU - Iacucci, M

AU - Shivaji, U N

PY - 2024/1/24

Y1 - 2024/1/24

U2 - 10.1093/ecco-jcc/jjad212.0678

DO - 10.1093/ecco-jcc/jjad212.0678

M3 - Meeting abstract

SN - 1873-9946

VL - 18

SP - i1072-i1072

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - Supplement_1

T2 - 19th Congress of ECCO

Y2 - 21 July 2024 through 24 July 2024

ER -

P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn’s Disease – results from a tertiary IBD centre

Access to Document

Press/Media

Researcher from University Hospitals Birmingham Reports on Findings in Crohn's Disease (P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn's Disease - results from a tertiary IBD centre)

Cite this